DGAP-News: STADA Arzneimittel AG / Key word(s): Bond
STADA Arzneimittel AG: Consent Solicitation for STADA Euro bond 2015/2022

08.06.2018 / 15:00
The issuer is solely responsible for the content of this announcement.


Bad Vilbel, June 8, 2018 - STADA Arzneimittel AG ("STADA") has today published the solicitation to the noteholders of the STADA Euro bond 2015/2022 (ISIN: XS1213831362, WKN: A14KJP, Common Code: 121383136) (the "STADA 2015 Notes"), to vote without a physical meeting with the object of appointing a common representative and making related mechanical amendments to the conditions of the STADA 2015 Notes (the "Consent Solicitation").

This modification to the STADA 2015 Notes is being arranged by STADA in connection with the provision of credit support by STADA and certain of its subsidiaries under the 2017 financing provided to its majority shareholder, Nidda Healthcare GmbH (the "Security"). The appointment of the common representative of the STADA 2015 Notes is designed to procure the extension of the Security to the holders of the STADA 2015 Notes on an equal and rateable basis with Nidda Healthcare GmbH's creditors under the 2017 financing. Accordingly, holders of the STADA 2015 Notes are encouraged to attend the noteholder meeting set out in the Consent Solicitation.

STADA also intends to offer to acquire STADA 2015 Notes at par plus accrued interest (to the date of acquisition) giving those holders who do not wish to participate in the proposed consents the ability to sell their STADA 2015 Notes. Details and conditions of the related tender offer for cash will be announced separately and nearer the time for the vote in respect of the Consent Solicitation.

Contact:
STADA Arzneimittel AG / Corporate Treasury / Frank Seiler / Stadastrasse 2-18 / 61118 Bad Vilbel - Germany / Tel.: +49 (0) 6101 603-4476 / Fax: +49 (0) 6101 603-3721 / E-mail: frank.seiler@stada.de

Or visit us on the Internet at www.stada.com

 



08.06.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803
WKN: 725180
Indices: SDAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

693883  08.06.2018 

fncls.ssp?fn=show_t_gif&application_id=693883&application_name=news&site_id=zonebourse